This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Oral lyophilisate containing desmopressin acetate

Drugs List

  • desmopressin 25microgram oral lyophilisates sugar-free
  • desmopressin 50microgram oral lyophilisates sugar-free
  • NOQDIRNA 25microgram oral lyophilisate tablet
  • NOQDIRNA 50microgram oral lyophilisate tablet
  • Therapeutic Indications


    Nocturia in females
    Nocturia in males

    Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.



    Females: 25 micrograms daily, 1 hour before bedtime.
    Males: 50 micrograms daily, 1 hour before bedtime.


    Females: 25 micrograms daily, 1 hour before bedtime.
    Males: 50 micrograms daily, 1 hour before bedtime.


    Children under 18 years
    Cardiac impairment
    Habitual polydipsia
    Psychogenic polydipsia
    Renal impairment - creatinine clearance below 50ml/minute
    Syndrome of inappropriate ADH secretion

    Precautions and Warnings

    Disorder of fluid balance
    Bladder disorder
    Bladder outflow obstruction
    Chronic renal disorder
    Cystic fibrosis
    Electrolyte imbalance
    Ischaemic heart disease

    Limit fluids for 1 hr before & 8 hrs after administration
    Elderly: monitor serum sodium before therapy, in week 1 & at 1 month
    Monitor fluid and electrolyte status
    Pregnancy: Monitor blood pressure due to increased risk of pre-eclampsia
    Suspend dose if vomiting/diarrhoea occurs until fluid/electrolytes normal
    Discontinue immediately if hyponatraemia occurs
    Advise patients to avoid excessive fluid intake

    Pregnancy and Lactation


    Use desmopressin with caution in pregnancy.

    Data on a limited number of exposed pregnancies indicate no adverse effects of desmopressin on pregnancy or on the health of the foetus/new-born child.

    Monitor blood pressure in pregnant patients due to the increased risk of pre-eclampsia.

    Animal studies do not indicate any direct or indirect harmful effects with pregnancy, embryonic/foetal development, parturition or postnatal development. Animal reproduction studies have shown no clinical relevant effects on parents and offspring. In vitro analysis of human cotyledon models have shown that there is no transplacental transport of desmopressin when administered at therapeutic concentration corresponding to the recommended dose.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Desmopressin is considered safe for use in breastfeeding.

    No adverse effects have been reported using this drug during breastfeeding.

    Results from analyses of milk from nursing mothers receiving high dose desmopressin (300 micrograms intranasally) indicated that the amounts of desmopressin that may be transferred to the child are considerably less than the amounts required to influence diuresis.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at


    Patients should be advised to hold the drug under the tongue and avoid swallowing until dissolved.

    Side Effects

    Abdominal discomfort
    Dry mouth
    Peripheral oedema


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2016

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Medications and Mothers' Milk, Sixteenth Edition (2014) Hale, T and Rowe, H, Hale Publishing, Plano, Texas.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Desmopressin. Last revised: 07 September 2013
    Last accessed: 19 October 2016

    Summary of Product Characteristics: Noqdirna 25 microgram oral lyophilisate. Ferring Pharmaceuticals Ltd. Revised May 2016.
    Summary of Product Characteristics: Noqdirna 50 microgram oral lyophilisate. Ferring Pharmaceuticals Ltd. Revised May 2016.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.